Point Of Care Infectious Disease Testing Market Challenges: Regulatory and Compliance Issues

The global point of care infectious disease testing market size is expected to reach USD 15.76 billion by 2030, registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

 

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in point-of-care infectious disease diagnostics market through to 2025.

 

For instance, development of a new ‘lab-on-a-disc’ technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.

 

 

Access the Point Of Care Infectious Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Disease (HIV POC, Clostridium Difficile POC), By End-use, By Region, And Segment Forecasts, 2024 - 2030

 

 

Point Of Care Infectious Disease Testing Market Report Highlights

·        COVID-19 segment dominated the market and accounted for a share of 67% in 2023. This high percentage can be attributed to the rising number of infectious cases and need for fast and accessible diagnostics testing solutions.

 

·        Lateral flow immunoassay is expected to register the fastest CAGR of 5.7% during the forecast period. The growth can be attributed to increasing prevalence of infectious diseases such as respiratory disease and technological advancements in point of care diagnostics device.

 

·        The home segment is projected to grow at the fastest CAGR of 5.5% over the forecast period, owing to increasing adoption of point of care testing among geriatric population and increasing emphasis on personalized and preventive home care facilities.

 

·        Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support

 

Key Point Of Care Infectious Disease Testing Company Insights

Some of the key companies in the point of care infectious disease testing market include Abbott; Thermo Fisher Scientific Inc; F. Hoffmann-La Roche Ltd; Siemens Healthineers; Quest Diagnostics Incorporated. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

 

 

Order your free sample copy of “Point Of Care Infectious Disease Testing Market Report 2024 - 2030, published by Grand View Research

 

Key Point Of Care Infectious Disease Testing Companies:

The following are the leading companies in the point of care infectious disease testing market. These companies collectively hold the largest market share and dictate industry trends.

 

·        Abbott

·        Thermo Fisher Scientific Inc

·        F. Hoffmann-La Roche Ltd

·        Siemens Healthineers

·        Becton, Dickinson & Company

·        Chembio Diagnostics Inc.

·        Trinity Biotech

·        Cardinal Health

·        Quest Diagnostics Incorporated

·        Bio-Rad Laboratories Inc.

·        bioMérieux SA

·        Sight Diagnostics Ltd.

·        Gene POC

·        Trivitron Healthcare

·        OJ-Bio Ltd.

·        Ortho-Clinical Diagnostics.

Recent Developments

·        In January 2024, Roche acquired LumiraDx’s point of care technology. The LumiraDx’s platform includes a range of immunoassay and clinical chemical tests. The addition of LumiraDx’s to Roche may enable the company to transform testing at the point of care.

 

·        In February 2023, Thermo Fisher partnered with Mylab, announced to launch made-in-India RTPCR kits for infectious disease in India. Mylab in partnership with Thermo Fisher aims to access of the test to a greater portion of the population in India as well as the world.

 

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  sales@grandviewresearch.com